Get the latest news, insights, and market updates on NVO (Novo Nordisk A/S). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Novo Nordisk (CPSE:NOVO B) Valuation After A Challenging Year For Shareholders
How Novo Nordisk shares look after a challenging year Novo Nordisk (CPSE:NOVO B) enters 2026 after a mixed stretch, with the share price showing a 20.3% decline over the past month and a modest 0.2% decline over the past 3 months. Over longer periods, the stock is down 6.2% year to date and 45.7% over the past year, while the 5 year total return sits at 54.5%. That backdrop sets the stage for looking at how current fundamentals compare with this weaker recent share performance. See our latest... Feb 18, 2026 - $NVO
Hims And Hers Weighs Legal Risks Against Growth In Longevity Pivot
Hims & Hers Health (NYSE:HIMS) launched a compounded semaglutide weight loss pill, then quickly discontinued it after a patent infringement lawsuit from Novo Nordisk. The company is under increased FDA scrutiny over compounded medications and has been referred to the US Department of Justice regarding possible marketing of unapproved drugs. Following these developments, Hims & Hers is shifting focus toward longevity and peptide related offerings. Hims & Hers Health, a telehealth platform... Feb 18, 2026 - $NVO
Goodpath Expands Direct-to-Employer and Self-Pay Access to Wegovy Through Novo Nordisk Collaboration
Goodpath, the virtual integrative care provider for chronic conditions, today announced direct-to-employer (DTE) and self-pay access to Wegovy®, including both injectable and newly-approved oral formulations, through a collaboration with Novo Nordisk. This gives employers additional flexibility to offer GLP-1 medications outside the traditional pharmacy benefit, with transparent pricing. The model enables employers to decide whether and how to subsidize Wegovy® and set employee cost share, while Feb 18, 2026 - $NVO
Deutsche Bank Cite Near-Term Growth Concerns For Hims & Hers Health, Inc. (HIMS) Following GLP-1 Launch Reversal
Hims & Hers Health, Inc. (NYSE:HIMS) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best healthcare stocks on our list. TheFly reported on February 10 that Deutsche Bank lowered its price target on HIMS to $31 from $42 and maintained a Hold rating on […] Feb 18, 2026 - $NVO
Novo Nordisk Faces Wegovy Dose Expansion And New Generic Competition
European Commission approves a higher 7.2 mg maintenance dose of Wegovy for obesity treatment across the EU. Dr Reddy's Laboratories prepares to launch a lower cost generic version of Wegovy in India. These developments arrive as Novo Nordisk, ticker CPSE:NOVO B, trades at DKK308.45 with mixed multi year share returns. Novo Nordisk, CPSE:NOVO B, is tightening its focus on obesity care with an EU wide green light for a higher 7.2 mg Wegovy dose. This could be relevant for patients and... Feb 17, 2026 - $NVO
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple